Details of the Drug

General Information of Drug (ID: DM3OBQF)

Drug Name

Belimumab

Synonyms

Belimumab (USAN); LymphoStat-B; LymphoStat-B (TN)

Indication

Disease Entry	ICD 11	Status	REF
Membranous glomerulonephritis	N.A.	Approved	[1]
Systemic lupus erythematosus	4A40.0	Approved	[2]
------------------------------------------------------------------------------------

Affected Organisms

Humans and other mammals

ATC Code

L04AA26: Belimumab

L04AA: Selective immunosuppressants

L04A: IMMUNOSUPPRESSANTS

L04: IMMUNOSUPPRESSANTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Antibody

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 19.4 days [3]
Metabolism: The drug is metabolized via proteolytic enzymes []

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell-activating factor (TNFSF13B)	TTWMIDN	TN13B_HUMAN	Not Available	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Belimumab (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Belimumab and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[5]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Belimumab and Tecfidera.	Multiple sclerosis [8A40]	[6]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Belimumab and Siponimod.	Multiple sclerosis [8A40]	[7]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Belimumab and Ocrelizumab.	Multiple sclerosis [8A40]	[8]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Belimumab and Ozanimod.	Multiple sclerosis [8A40]	[9]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Belimumab when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[10]
-----------


⏷ Show the Full List of 6 DDI Information of This Drug

References

1	[Membranous glomerulonephritis (MGN), ongoing studies]. G Ital Nefrol. 2017 Sep 28;34(5):113-118.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6887).
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
5	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
6	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
7	Cerner Multum, Inc. "Australian Product Information.".
8	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
9	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]